Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients

Respirology

Volumn 17, Issue 2, 2012, Pages 354-362

  Kawai, Yasuhiro ^a   Miyashita, Naoyuki ^b   Yamaguchi, Tetsuya ^a   Saitoh, Aki ^a   Kondoh, Eisuke ^a   Fujimoto, Hiroki ^a   Teranishi, Hideto ^a   Inoue, Mika ^a   Wakabayashi, Tokio ^a   Akaike, Hiroto ^a   Ogita, Satoko ^a   Kawasaki, Kozo ^a   Terada, Kihei ^a   Kishi, Fumio ^b   Ouchi, Kazunobu ^a  

^a Department of Pediatrics ^*  (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

23S ribosomal ribonucleic acid; macrolide resistant; minocycline; Mycoplasma pneumoniae; polymerase chain reaction

Indexed keywords

AZITHROMYCIN; BACTERIAL DNA; BACTERIAL RNA; CLARITHROMYCIN; CODEINE PHOSPHATE; MACROLIDE; MINOCYCLINE; PROCATEROL; PROCATEROL HYDROCHLORIDE HYDRATE; RNA 23S; TIPEPIDINE; TIPEPIDINE HIBENZATE; TULOBUTEROL; UNCLASSIFIED DRUG;

ADOLESCENT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; MACROLIDE RESISTANT MYCOPLASMA PNEUMONIAE; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NASOPHARYNX; NONHUMAN; POINT MUTATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MACROLIDES; MALE; MYCOPLASMA PNEUMONIAE; PNEUMONIA, MYCOPLASMA; POINT MUTATION; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RNA, RIBOSOMAL, 23S; TREATMENT OUTCOME;

EID: 84856306131     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2011.02102.x     Document Type: Article

References (27)

1. Okazaki N, Narita M, Yamada S, et al,. Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol. Immunol. 2001; 45: 617-20. (Pubitemid 32785787)
2. Matsuoka M, Narita M, Okazaki N, et al,. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob. Agents Chemother. 2004; 48: 4624-30. (Pubitemid 39577663)
3. Morozumi M, Iwata S, Hasegawa K, et al,. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob. Agents Chemother. 2008; 52: 348-50.
4. Yanagihara K, Izumikawa K, Higa F, et al,. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection. Intern. Med. 2009; 48: 527-35.
5. Takizawa H, Desaki M, Ohtoshi T, et al,. Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells: a potential mechanism of its anti-inflammatory action. Biochem. Biophys. Res. Commun. 1995; 210: 781-6.
6. Kohyama T, Takizawa H, Kawasaki S, et al,. Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. Antimicrob. Agents Chemother. 1999; 43: 907-11. (Pubitemid 29165756)
7. Abe S, Nakamura H, Inoue S, et al,. A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients. J. Infect. Chemother. 2009; 15: 380-3.
8. Ichiyama T, Nishikawa M, Yoshitomi T, et al,. Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob. Agents Chemother. 2001; 45: 44-7. (Pubitemid 32039091)
9. Friedlander AL, Albert RK,. Chronic macrolide therapy in inflammatory airways diseases. Chest 2010; 138: 1202-12.
10. Koyama H, Geddes DM,. Erythromycin and diffuse panbronchiolitis. Thorax 1997; 52: 915-18. (Pubitemid 27473937)
11. Kudoh S, Azuma A, Yamamoto M, et al,. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am. J. Respir. Crit. Care Med. 1998; 157: 1829-32.
12. Saiman L, Marshall BC, Mayer-Hamblett N, et al,. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290: 1749-56. (Pubitemid 37430625)
13. The Committee for the Guidelines in Management of Respiratory Infectious Diseases in Children., Uehara S, Sunagawa K, (eds) Guideline for the Management of Respiratory Infectious Diseases in Children. Japanese Society of Pediatric Pulmonology/Japanese Society for Pediatric Infectious Diseases, Tokyo, 2004 (in Japanese).
14. Miyashita N, Fukano H, Mouri K, et al,. Community-acquired pneumonia in Japan: a prospective ambulatory and hospitalized patient study. J. Med. Microbiol. 2005; 54: 395-400. (Pubitemid 40489548)
15. Miyashita N, Obase Y, Ouchi K, et al,. Clinical features of severe Mycoplasma pneumoniae pneumonia in adults admitted to an intensive care unit. J. Med. Microbiol. 2007; 56: 1625-9. (Pubitemid 350276512)
16. Miyashita N, Kawai Y, Yamaguchi T, et al,. Clinical potential of diagnostic methods for the rapid diagnosis of Mycoplasma pneumoniae pneumonia in adults. Eur. J. Clin. Microbiol. Infect. Dis. 2011; 30: 439-46.
17. Lucier TS, Heitzman K, Liu SK, et al,. Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 1995; 39: 2770-3.
18. Li X, Atkinson TP, Hagood J, et al,. Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates. Pediatr. Infect. Dis. J. 2009; 28: 693-6.
19. Liu Y, Ye X, Zhang H, et al,. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob. Agents Chemother. 2009; 53: 2160-2.
20. Peuchant O, Menard A, Renaudin H, et al,. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J. Antimicrob. Chemother. 2009; 64: 52-8.
21. Wolff BJ, Thacker WL, Schwartz SB, et al,. Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob. Agents Chemother. 2008; 52: 3542-9.
22. Xin D, Mi Z, Han X, et al,. Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrob. Agents Chemother. 2009; 53: 2158-9.
23. Morozumi M, Takahashi T,., Ubukata K,. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J. Infect. Chemother. 2010; 16: 78-86.
24. Suzuki S, Yamazaki T, Narita M, et al,. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 2006; 50: 709-12. (Pubitemid 43190986)
25. Waites KB, Talkington DF,. Mycoplasma pneumoniae and its role as a human pathogen. Clin. Microbiol. Rev. 2004; 17: 697-728. (Pubitemid 39372513)
26. Atkinson TP, Balish MF, Waites KB,. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol. Rev. 2008; 32: 956-73.
27. Matsubara K, Morozumi M, Okada T, et al,. A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients. J. Infect. Chemother. 2009; 15: 380-3.